Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lorente

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Journal of Pediatric Hematology/Oncology|May 2, 2015
Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution ExperienceRobert Diaz-Beveridge, David Lorente, Barbara Torres, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Springerplus|November 21, 2013
Advantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancerAna Santaballa, Helena De La Cueva, Carmen Salvador, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 16, 2024
Correction: Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective studyMaria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2024
Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective studyMaria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, et al.
European Urology|April 28, 2016
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate CancerJonathan Welti, Daniel Nava Rodrigues, Adam Sharp, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2021
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitorsClara García-Carro, Mónica Bolufer, Roxana Bury, et al.
European Urology|August 11, 2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre AnalysisKlaus Brasso, Frederik B Thomsen, Andres J Schrader, et al.
European Urology|April 2, 2014
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abirateronePraful Ravi, Joaquin Mateo, David Lorente, et al.
Frontiers in Oncology|December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancerAlexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Journal of Pediatric Hematology/Oncology|May 2, 2015
Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution ExperienceRobert Diaz-Beveridge, David Lorente, Barbara Torres, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Springerplus|November 21, 2013
Advantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancerAna Santaballa, Helena De La Cueva, Carmen Salvador, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 16, 2024
Correction: Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective studyMaria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2024
Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective studyMaria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, et al.
European Urology|April 28, 2016
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate CancerJonathan Welti, Daniel Nava Rodrigues, Adam Sharp, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2021
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitorsClara García-Carro, Mónica Bolufer, Roxana Bury, et al.
European Urology|August 11, 2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre AnalysisKlaus Brasso, Frederik B Thomsen, Andres J Schrader, et al.
European Urology|April 2, 2014
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abirateronePraful Ravi, Joaquin Mateo, David Lorente, et al.
Frontiers in Oncology|December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancerAlexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Pageof 8